Caris Life Sciences Q3 2026 revenue up 27% to $275.4 million
Caris Life Sciences reported a 27% revenue increase to $275.4 million for Q3 2026, surpassing prior-year performance in molecular profiling services and raising full-year revenue guidance to a range of $1.04 to $1.05 billion.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed